AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1827967 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 30
Study 7034617 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% Norepinephrine dipivalylate
Number of subjects: 12
Study 7034617 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31907017 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of Infant Pain Practice Change (ImPaC) Resource for six months
Number of subjects: 18
Study 31907017 — intervention group
Group type: COMPARATOR
Intervention: Standard practice (SP)
Number of subjects: 18
Study 30551157 — intervention group
Group type: EXPERIMENTAL
Intervention: ER + IVRE
Number of subjects: 85
Study 30551157 — intervention group
Group type: COMPARATOR
Intervention: ER + RP
Number of subjects: 85
Study 27893087 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care plus 2 years of home‐based occupational therapy
Number of subjects: 180
Study 27893087 — intervention group
Group type: COMPARATOR
Intervention: Collaborative care alone (Control)
Number of subjects: 180
Study 25381032 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol (1,25 OH2D3) supplementation
Number of subjects: 0
Study 25381032 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-hydroxyvitamin D3 supplementation
Number of subjects: 0
Study 25381032 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22823871 — intervention group
Group type: EXPERIMENTAL
Intervention: α(1)-blockade (prazosin, 1 mg/20 kg body weight)
Number of subjects: 12
Study 22823871 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 20595648 — intervention group
Group type: EXPERIMENTAL
Intervention: Milled flaxseed (FXS, n = 13; 32 g/d)
Number of subjects: 34
Study 20595648 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed oil (FXO, n = 12; 13 g/d)
Number of subjects: 34
Study 20595648 — intervention group
Group type: COMPARATOR
Intervention: Control group (CTL, n = 9; no flax)
Number of subjects: 34
Study 17592102 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (2 mg/d)
Number of subjects: 630
Study 17592102 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (4 mg/d)
Number of subjects: 630
Study 16096436 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendmustine, methotrexate and 5-fluorouracil (BMF)
Number of subjects: 364
Study 16096436 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide, methotrexate and 5-fluorouracil (CMF)
Number of subjects: 364
Study 16096436 — intervention group
Group type: EXPERIMENTAL
Intervention: BMF
Number of subjects: 364
Study 16096436 — intervention group
Group type: COMPARATOR
Intervention: BMF and CMF
Number of subjects: 364
Study 12149202 — intervention group
Group type: EXPERIMENTAL
Intervention: ADE (cytarabine 100 mg/m(2)/d by 7‐day infusion, daunorubicin 60 mg/m(2) and etoposide 100 mg/m(2) daily for 3 days)
Number of subjects: 120
Study 12149202 — intervention group
Group type: COMPARATOR
Intervention: ADEP (daunorubicin 40 mg/m(2) and etoposide 60 mg/m(2) for 3 days with PSC‐833, 2.8 mg/kg over 2 hours, and then 10 mg/kg/d by 3‐day infusion)
Number of subjects: 120
Study 12149202 — intervention group
Group type: EXPERIMENTAL
Intervention: ADE (for patients with PSC‐833‐modulated dye efflux)
Number of subjects: 120
Study 12149202 — intervention group
Group type: COMPARATOR
Intervention: ADEP (for patients with PSC‐833‐modulated dye efflux)
Number of subjects: 120
Study 12149202 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 120
Study 12149202 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease-free survival
Number of subjects: 120
Study 10084159 — intervention group
Group type: EXPERIMENTAL
Intervention: HPMC-10 (10% hydroxypropyl methylcellulose)
Number of subjects: 8
Study 10084159 — intervention group
Group type: COMPARATOR
Intervention: Tegretol CR 200 (commercially available controlled-release carbamazepine preparation)
Number of subjects: 8
Study 7668855 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive model for fall risk assessment
Number of subjects: 338
Study 7668855 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-validation of predictive model
Number of subjects: 338
Study 7668855 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factor model including seven risk factors
Number of subjects: 338
Study 2111251 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg diclofenac potassium three times daily for 7 days
Number of subjects: 93
Study 2111251 — intervention group
Group type: COMPARATOR
Intervention: 20 mg/day piroxicam for 7 days
Number of subjects: 93
Study 2111251 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 7 days
Number of subjects: 93
Study 6963332 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (ASA), 600 mg, p.o., twice daily for 2 years
Number of subjects: 66
Study 6963332 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 66
Study 30688523 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with 5‐fluorouracil and oxaliplatin (FOLFOX)
Number of subjects: 1000
Study 30688523 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant chemoradiation
Number of subjects: 1000
Study 29138273 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment (INT) of type 1 diabetes
Number of subjects: 1213
Study 29138273 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (CONV)
Number of subjects: 1213
Study 29138273 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment (INT)
Number of subjects: 1213
Study 27103060 — intervention group
Group type: EXPERIMENTAL
Intervention: Modelling strategy
Number of subjects: 204
Study 27103060 — intervention group
Group type: EXPERIMENTAL
Intervention: Reward strategy
Number of subjects: 204
Study 27103060 — intervention group
Group type: COMPARATOR
Intervention: Neutral instructions
Number of subjects: 204
Study 27103060 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal encouragement (for children low in Reward Sensitivity)
Number of subjects: 204
Study 27103060 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate reward (for children high in Reward Sensitivity)
Number of subjects: 204
Study 25938131 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical sodium nitrite 0.5% cream
Number of subjects: 18
Study 25938131 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical sodium nitrite 1.0% cream
Number of subjects: 18
Study 25938131 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical sodium nitrite 1.5% cream
Number of subjects: 18
Study 25938131 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical sodium nitrite 1.8% cream
Number of subjects: 18
Study 25938131 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical sodium nitrite 2.0% cream
Number of subjects: 18
Study 25938131 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-hoc analysis of pain
Number of subjects: 18
Study 21967073 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual virtual reality exposure therapy
Number of subjects: 0
Study 21967073 — intervention group
Group type: EXPERIMENTAL
Intervention: Group cognitive-behavioral therapy
Number of subjects: 0
Study 21967073 — intervention group
Group type: EXPERIMENTAL
Intervention: Outcome expectancy
Number of subjects: 0
Study 18940275 — intervention group
Group type: EXPERIMENTAL
Intervention: Age at menarche
Number of subjects: 71
Study 18940275 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight concerns
Number of subjects: 71
Study 17502577 — intervention group
Group type: EXPERIMENTAL
Intervention: Otamixaban (highest dose)
Number of subjects: 947
Study 17502577 — intervention group
Group type: EXPERIMENTAL
Intervention: Otamixaban (doses 1 to 5)
Number of subjects: 947
Study 17502577 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 947
Study 17290435 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to approximately 1600 mT (twice)
Number of subjects: 27
Study 17290435 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to approximately 800 mT
Number of subjects: 27
Study 17290435 — intervention group
Group type: EXPERIMENTAL
Intervention: Negligible static field exposure
Number of subjects: 27
Study 17290435 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized head movements generating approximately 300 and approximately 150 mT.s(‐1) r.m.s.
Number of subjects: 27
Study 17290435 — intervention group
Group type: COMPARATOR
Intervention: Stable head position (control session)
Number of subjects: 27
Study 14981398 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination with protease inhibitor (PI) early
Number of subjects: 1407
Study 14981398 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination without protease inhibitor (PI)
Number of subjects: 1407
Study 14981398 — intervention group
Group type: EXPERIMENTAL
Intervention: Monotherapy (monoRx) early
Number of subjects: 1407
Study 14981398 — intervention group
Group type: EXPERIMENTAL
Intervention: Monotherapy (monoRx) late
Number of subjects: 1407
Study 14981398 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination without protease inhibitor (PI) late
Number of subjects: 1407
Study 14981398 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination with protease inhibitor (PI) late
Number of subjects: 1407
Study 11037592 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic fetal monitoring (EFM)
Number of subjects: 0
Study 11037592 — intervention group
Group type: COMPARATOR
Intervention: Intermittent auscultation
Number of subjects: 0
Study 11037592 — intervention group
Group type: COMPARATOR
Intervention: Scalp blood sampling
Number of subjects: 0
Study 11037592 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal pulse oximetry and ST-analysis of fetal ECG (STAN)
Number of subjects: 0
Study 8769693 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN‐alpha n1
Number of subjects: 527
Study 8769693 — intervention group
Group type: COMPARATOR
Intervention: No IFN (standard chemotherapy: busulphan or hydroxyurea)
Number of subjects: 527
Study 1732125 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone infusions (0.2 micrograms.kg‐1.min‐1)
Number of subjects: 8
Study 1732125 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 8
Study 6482168 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin
Number of subjects: 0
Study 6482168 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin
Number of subjects: 0
Study 6482168 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin
Number of subjects: 0
Study 6482168 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 0
Study 31912603 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 0
Study 31912603 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30719935 — intervention group
Group type: EXPERIMENTAL
Intervention: Brinzolamide
Number of subjects: 90
Study 30719935 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol
Number of subjects: 90
Study 30719935 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost
Number of subjects: 90
Study 30719935 — intervention group
Group type: COMPARATOR
Intervention: Artificial tear (Sodium hyaluronate)
Number of subjects: 90
Study 30016756 — intervention group
Group type: EXPERIMENTAL
Intervention: High-noise workdays (76.8 dBA, SD: 6.2)
Number of subjects: 40
Study 30016756 — intervention group
Group type: COMPARATOR
Intervention: Low-noise workdays (61.0 dBA, SD: 7.1)
Number of subjects: 40
Study 30016756 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-shift personal noise exposure
Number of subjects: 40
Study 27099761 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive servoventilation (ASV)
Number of subjects: 43
Study 27099761 — intervention group
Group type: COMPARATOR
Intervention: Oxygen therapy
Number of subjects: 43
Study 24864063 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified DA-CPR instructions
Number of subjects: 75
Study 24864063 — intervention group
Group type: COMPARATOR
Intervention: Conventional DA-CPR instructions
Number of subjects: 75
Study 20877298 — intervention group
Group type: EXPERIMENTAL
Intervention: Bumetanide, Frusemide, Torsemide
Number of subjects: 95
Study 20877298 — intervention group
Group type: EXPERIMENTAL
Intervention: C825T in GNB3
Number of subjects: 95
Study 20877298 — intervention group
Group type: EXPERIMENTAL
Intervention: Val32Met in ANP
Number of subjects: 95
Study 20877298 — intervention group
Group type: EXPERIMENTAL
Intervention: Ter152Arg in ANP
Number of subjects: 95
Study 20877298 — intervention group
Group type: EXPERIMENTAL
Intervention: ANP Arg152-alleles
Number of subjects: 95
Study 20877298 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE insertion/deletion polymorphism
Number of subjects: 95
Study 20877298 — intervention group
Group type: EXPERIMENTAL
Intervention: Gly460Trp in ADD1
Number of subjects: 95
Study 20877298 — intervention group
Group type: EXPERIMENTAL
Intervention: GNB3 T-alleles
Number of subjects: 95
Study 20877298 — intervention group
Group type: EXPERIMENTAL
Intervention: Common genetic impact
Number of subjects: 95
Study 20877298 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacokinetics
Number of subjects: 95
Study 19287176 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week vocal training program (n = 14)
Number of subjects: 43
Study 19287176 — intervention group
Group type: COMPARATOR
Intervention: No-training control group (n = 29)
Number of subjects: 43
Study 17615974 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of DD3 mRNA in urine of prostate cancer patients
Number of subjects: 80
Study 17615974 — intervention group
Group type: COMPARATOR
Intervention: Detection of DD3 mRNA in urine of BPH patients
Number of subjects: 80
Study 17615974 — intervention group
Group type: COMPARATOR
Intervention: Detection of DD3 mRNA in urine of healthy male volunteers
Number of subjects: 80
Study 15016558 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03%
Number of subjects: 269
Study 15016558 — intervention group
Group type: COMPARATOR
Intervention: Latanoprost 0.005%
Number of subjects: 269
Study 11668421 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin certoparin (8000 antifactor Xa U b.i.d.)
Number of subjects: 393
Study 11668421 — intervention group
Group type: COMPARATOR
Intervention: Adjusted-dose intravenous unfractionated heparin (UFH)
Number of subjects: 393
Study 9835755 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 micrograms of oral clonidine
Number of subjects: 40
Study 9835755 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 8208915 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-chamber pacing (DDD)
Number of subjects: 16
Study 8208915 — intervention group
Group type: COMPARATOR
Intervention: Single-chamber ventricular demand pacing (VVI)
Number of subjects: 16
Study 2659295 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam
Number of subjects: 69
Study 2659295 — intervention group
Group type: COMPARATOR
Intervention: AMG
Number of subjects: 69
Study 31511563 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoactive compounds (CANDO platform predictions)
Number of subjects: 428
Study 31511563 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific tryptamines
Number of subjects: 428
Study 31511563 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 428
Study 31511563 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabinoids
Number of subjects: 428
Study 29061968 — intervention group
Group type: EXPERIMENTAL
Intervention: Olodaterol 5 µg QD via Respimat®
Number of subjects: 1379
Study 29061968 — intervention group
Group type: COMPARATOR
Intervention: Formoterol 12 µg BID
Number of subjects: 1379
Study 29061968 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1379
Study 25211714 — intervention group
Group type: EXPERIMENTAL
Intervention: POWER intervention (8 sessions)
Number of subjects: 521
Study 25211714 — intervention group
Group type: COMPARATOR
Intervention: Control (single standard-of-care STI prevention session)
Number of subjects: 521
Study 24386960 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A injection (50 U injected intracutaneously into 6-20 sites)
Number of subjects: 150
Study 24386960 — intervention group
Group type: COMPARATOR
Intervention: Surgical excision of the apocrine glands
Number of subjects: 150
Study 24386960 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A injection
Number of subjects: 150
Study 21733136 — intervention group
Group type: EXPERIMENTAL
Intervention: Foster Care (FC)
Number of subjects: 136
Study 21733136 — intervention group
Group type: COMPARATOR
Intervention: Care as Usual (CAU)
Number of subjects: 136
Study 18572184 — intervention group
Group type: EXPERIMENTAL
Intervention: Absence of resolution group (group 2)
Number of subjects: 81
Study 18572184 — intervention group
Group type: COMPARATOR
Intervention: Partial resolution group (group 1)
Number of subjects: 81
Study 17334286 — intervention group
Group type: EXPERIMENTAL
Intervention: Total disc replacement (TDR)
Number of subjects: 17
Study 17334286 — intervention group
Group type: COMPARATOR
Intervention: Circumferential fusion
Number of subjects: 17
Study 17334286 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 17
Study 14723752 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 200 mg by mouth followed in two days by vaginal then oral misoprostol (Aberdeen regimen)
Number of subjects: 18
Study 14723752 — intervention group
Group type: COMPARATOR
Intervention: Dilation and evacuation (D&E)
Number of subjects: 18
Study 12805252 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate meal (3.43 MJ, 166g carbohydrates, 38g proteins)
Number of subjects: 19
Study 12805252 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat meal (3.35 MJ, 70g fat, 36g proteins)
Number of subjects: 19
Study 12805252 — intervention group
Group type: COMPARATOR
Intervention: Fasting
Number of subjects: 19
Study 10355844 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyruvate supplementation (6 g/d)
Number of subjects: 26
Study 10355844 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 7721404 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan 10 mg
Number of subjects: 24
Study 7721404 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan 50 mg
Number of subjects: 24
Study 7721404 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 2201664 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral L-Dopa
Number of subjects: 10
Study 2201664 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 7030443 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine plus high dose propranolol
Number of subjects: 10
Study 7030443 — intervention group
Group type: COMPARATOR
Intervention: Chlorpromazine alone
Number of subjects: 10
Study 31084292 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician intervention (DECIDE‐PC training sessions)
Number of subjects: 312
Study 31084292 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient activation and depression symptoms
Number of subjects: 312
Study 27609528 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative-pressure wound therapy
Number of subjects: 71
Study 25575201 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal adhesives (two types)
Number of subjects: 120
Study 25575201 — intervention group
Group type: COMPARATOR
Intervention: Self-etch adhesive (Clearfil SE)
Number of subjects: 120
Study 25575201 — intervention group
Group type: EXPERIMENTAL
Intervention: Etch-and-rinse mode
Number of subjects: 120
Study 25575201 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-etch mode
Number of subjects: 120
Study 25329583 — intervention group
Group type: EXPERIMENTAL
Intervention: S-100 calcium-binding protein B (S-100B) levels
Number of subjects: 50
Study 25329583 — intervention group
Group type: EXPERIMENTAL
Intervention: Beck Depression Inventory II (BDI-II) scores at baseline and discharge
Number of subjects: 50
Study 25329583 — intervention group
Group type: COMPARATOR
Intervention: Baseline S-100B levels, high-sensitivity C-reactive protein, interleukin-6 levels
Number of subjects: 50
Study 22938011 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage after moisturizer application
Number of subjects: 13
Study 22938011 — intervention group
Group type: COMPARATOR
Intervention: No massage after moisturizer application
Number of subjects: 13
Study 19112224 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodixanol (Visipaque) 50 mL
Number of subjects: 62
Study 19112224 — intervention group
Group type: EXPERIMENTAL
Intervention: Iohexol (Omnipaque) 50 mL
Number of subjects: 62
Study 17660641 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothbrush with bristle design 1
Number of subjects: 16
Study 17660641 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothbrush with bristle design 2
Number of subjects: 16
Study 17660641 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothbrush with bristle design 3
Number of subjects: 16
Study 17660641 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothbrush with bristle design 4
Number of subjects: 16
Study 15134985 — intervention group
Group type: EXPERIMENTAL
Intervention: 153Sm-lexidronam
Number of subjects: 152
Study 15134985 — intervention group
Group type: COMPARATOR
Intervention: 152Sm (placebo)
Number of subjects: 152
Study 12420197 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-measurements of BP and heart rate in GP's room
Number of subjects: 210
Study 9438458 — intervention group
Group type: EXPERIMENTAL
Intervention: AutoPap 300 QC System
Number of subjects: 14914
Study 9438458 — intervention group
Group type: COMPARATOR
Intervention: Random QC process (10% random selection)
Number of subjects: 14914
Study 8285510 — intervention group
Group type: EXPERIMENTAL
Intervention: Multichannel cochlear implants
Number of subjects: 48
Study 3549804 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% minoxidil solution
Number of subjects: 96
Study 3549804 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% minoxidil solution
Number of subjects: 96
Study 3549804 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 30578883 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Number of subjects: 100
Study 30578883 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 25830322 — intervention group
Group type: EXPERIMENTAL
Intervention: rVSV-ZEBOV vaccine (3 million PFU, 20 million PFU, or 100 million PFU)
Number of subjects: 78